T Turpeenniemi-Hujanen

Summary

Affiliation: Oulu University Hospital
Country: Finland

Publications

  1. ncbi Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers
    T Turpeenniemi-Hujanen
    Department of Oncology and Radiotherapy, Oulu University Hospital, PL22, 90029 OYS, Finland
    Biochimie 87:287-97. 2005
  2. ncbi Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study
    Jenni K Peltonen
    Department of Oncology and Radiotherapy, Oulu University Hospital, University of Oulu, Oulu, Finland
    Head Neck Oncol 3:20. 2011
  3. ncbi Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer
    Juho Konsti
    FIMM Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland
    BMC Clin Pathol 11:3. 2011
  4. ncbi Matrix metalloproteinase 9 in the uterine cervix during tumor progression
    A Talvensaari-Mattila
    Department of Obstetrics and Gynecology, Oulu University Hospital, Oulu, Finland
    Int J Gynaecol Obstet 92:83-4. 2006
  5. ncbi Matrix metalloproteinases-2 and -9 in cervical cancer: different roles in tumor progression
    M Rauvala
    Department of Obstetrics and Gynecology, The University Hospital of Oulu, PL 24, FIN 90029 OYS, Oulu, Finland
    Int J Gynecol Cancer 16:1297-302. 2006

Collaborators

  • Jenni K Peltonen
  • Juho Konsti
  • M Rauvala
  • A Talvensaari-Mattila
  • Kaija Holli
  • Vesa Kataja
  • Risto Bloigu
  • Kirsi H Vahakangas
  • Jorma Isola
  • Heikki Joensuu
  • Harri Sihto
  • Paavo Paakko
  • Johan Lundin
  • Henni M Helppi
  • Liisa Sailas
  • Tiina Lehtimäki
  • Mikael Lundin
  • K Aglund
  • U Puistola
  • G Horvath
  • U Stendahl
  • R Willen

Detail Information

Publications5

  1. ncbi Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers
    T Turpeenniemi-Hujanen
    Department of Oncology and Radiotherapy, Oulu University Hospital, PL22, 90029 OYS, Finland
    Biochimie 87:287-97. 2005
    ..The growing amount of recent clinical data suggests that the impact of gelatinases on treatment decisions should be tested in clinical trials...
  2. ncbi Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study
    Jenni K Peltonen
    Department of Oncology and Radiotherapy, Oulu University Hospital, University of Oulu, Oulu, Finland
    Head Neck Oncol 3:20. 2011
    ..Despite the intense research in the area of squamous cell carcinomas of head and neck (HNSCC), long-term survival rate has not changed significantly in this malignancy during recent decades...
  3. ncbi Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer
    Juho Konsti
    FIMM Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland
    BMC Clin Pathol 11:3. 2011
    ..abstract:..
  4. ncbi Matrix metalloproteinase 9 in the uterine cervix during tumor progression
    A Talvensaari-Mattila
    Department of Obstetrics and Gynecology, Oulu University Hospital, Oulu, Finland
    Int J Gynaecol Obstet 92:83-4. 2006
  5. ncbi Matrix metalloproteinases-2 and -9 in cervical cancer: different roles in tumor progression
    M Rauvala
    Department of Obstetrics and Gynecology, The University Hospital of Oulu, PL 24, FIN 90029 OYS, Oulu, Finland
    Int J Gynecol Cancer 16:1297-302. 2006
    ..Intensive MMP-9 was noted in grade 1 tumors. We conclude that MMP-2 and MMP-9 have different roles in uterine cervical cancer. MMP-2 could be associated with aggressive behavior, but MMP-9 expression diminishes in high-grade tumors...